Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, J. H.
Right arrow Articles by Liu, F. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, J. H.
Right arrow Articles by Liu, F. F.

Clinical Cancer Research, Vol 3, Issue 4 507-514, Copyright © 1997 by American Association for Cancer Research


ARTICLES

Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines

JH Li, P Li, H Klamut and FF Liu
Departments of Radiation Oncology and Research, Princess Margaret Hospital/Ontario Cancer Institute, Toronto, Ontario, M5G 2M9 Canada.

Nasopharyngeal carcinoma (NPC) is a malignant disease of the head/neck region with a 5-year survival level of approximately 65%. To explore novel therapeutic strategies in the management of this disease, the potential of Ad5CMV-p53-mediated gene transfer to NPC cells was investigated in vitro. Two NPC cell lines, CNE-1 and CNE-2Z, were infected with either Ad5CMV-p53 or Ad5CMV-beta-galactosidase and evaluated for transduction efficiency and cytotoxicity. At a multiplicity of infection of 50 plaque-forming units (pfu)/cell, Ad5CMV-beta-galactosidase infection and beta-galactosidase expression were detected in almost 100% of treated NPC cells. High levels of recombinant p53 protein expression were also observed in the NPC cell lines when treated with Ad5CMV-p53 at 50 pfu/cell. Expression of recombinant p53 was dose and time dependent, with peak levels observed at 24 h. A marked increase in WAF1/CIP1 expression was also observed in NPC cells after Ad5CMV-p53 infection. Expression of bcl-2 and bax were minimally detectable at baseline; infection with Ad5CMV-p53 induced no changes in the protein levels in the NPC cells. Growth of NPC cells treated with Ad5CMV-p53 was observed to be significantly inhibited when determined by either the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or clonogenic assay. Infection with Ad5CMV-p53 at 25 pfu/cell resulted in survival levels of 0.35 and 11% in CNE-1 and CNE-2Z cells, respectively. Chromatin condensation and DNA fragmentation were also observed, demonstrating that these cells were undergoing apoptosis. However, when GM38 (normal human fibroblasts) were subjected to identical treatments, they demonstrated significantly lower infection efficiency and transgene expression and were resistant to Ad5CMV-p53-mediated cytotoxicity. These data demonstrate the efficacy of Ad5CMV-p53-mediated gene therapy in human NPC, thus warranting additional investigations of this therapeutic strategy.


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
A. W. C. Lee, J.-H. Li, W. Shi, A. Li, E. Ng, T.-J. Liu, H. J. Klamut, and F.-F. Liu
p16 Gene therapy: A potentially efficacious modality for nasopharyngeal carcinoma
Mol. Cancer Ther., October 1, 2003; 2(10): 961 - 969.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. A. Makitie, C. MacMillan, J. Ho, W. Shi, A. Lee, B. O'Sullivan, D. Payne, M. Pintilie, B. Cummings, J. Waldron, et al.
Loss of p16 Expression Has Prognostic Significance in Human Nasopharyngeal Carcinoma
Clin. Cancer Res., June 1, 2003; 9(6): 2177 - 2184.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
L. Chen, L. Wang, L. Zhu, S. Nie, J. Zhang, P. Zhong, B. Cai, H. Luo, and T. J. C. Jacob
Cell cycle-dependent expression of volume-activated chloride currents in nasopharyngeal carcinoma cells
Am J Physiol Cell Physiol, October 1, 2002; 283(4): C1313 - C1323.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-H. Li, M. Chia, W. Shi, D. Ngo, C. A. Strathdee, D. Huang, H. Klamut, and F.-F. Liu
Tumor-targeted Gene Therapy for Nasopharyngeal Carcinoma
Cancer Res., January 1, 2002; 62(1): 171 - 178.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Narimatsu, Y. Nagayama, K. Akino, M. Yasuda, T. Yamamoto, T.-t. Yang, A. Ohtsuru, H. Namba, S. Yamashita, H. Ayabe, et al.
Therapeutic Usefulness of Wild-Type p53 Gene Introduction in a p53-Null Anaplastic Thyroid Carcinoma Cell Line
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3668 - 3672.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.